Gene expression and therapy is the introduction of foreign nucleic acids into target cells to modify or compensate for gene defects, so as to treat diseases such as cancer, diabetes, autoimmune diseases and infectious diseases. The rate of removal of exposed nucleic acid is faster, and the rate of non-specific biological distribution and cell internalization is low, which cannot achieve the expected therapeutic effect. Non-viral vectors have low immunity, can be used for multiple injections and mass production, and have great potential for clinical gene therapy. Common non-viral vector transgenic methods include electroporation, calcium phosphate precipitation, and liposomes. Cationic liposomes are positively charged at the surface and can wrap DNA molecules into them through electrostatic interactions with nucleic acid phospholipids, forming a DNA-lipid complex. They can also be absorbed by negatively charged cell membranes at the surface and then transferred into the cell by membrane fusion or cell endocytosis, and occasionally by direct osmosis. A small portion of DNA can be released from the envelope and enter the cytoplasm, where it can then be further transported to the nucleus for transcription and expression.

CD Bioparticles' services with customized delivery strategies, precise designs and modifications of drugs or drug-contained cargos, and advanced technical platforms can help you to solve:

The challenges you might meet:

• The expression efficiency of exogenous genes is low
• Nucleic acids exposed in body fluids are removed quickly
• Nonspecific biological distribution of exposed nucleic acids
• The cell internalization rate of oligonucleotide chains is low
• No safe and effective carrier of nucleic acid is found
• Genes that need to be expressed cannot be accurately delivered to the target site
• The products of gene expression are unstable

Key features:

• Lipofection in Gene Expression Transporter lipids involved in gene expression
• Magnetofection in Gene Expression Magnetic beads that target transfected cells in vivo

Key benefits:

• Low immune rejection
• High transfection efficiency and good biocompatibility
• Low toxicity, safe operation
• Easy to modify and transform its structure
• Large-scale production can be achieved
• Surface active liposomes allowing the modification of the gene-loaded liposomes to achieve cell-targeting or tissue-targeting
• Suitable for in vitro and in vivo experiments
• Ready-to-use

Application candidates:

• Modify or compensate for genetic defects to treat a variety of diseases, such as cancer, diabetes, autoimmune diseases, etc.
• To produce therapeutic proteins and antibodies
• The exploitation of new species
• Imaging test in vivo